Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 3Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 17Active not recruiting 4Unknown 3Terminated 3Recruiting 3Suspended 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Other solid neoplasm 1CNS 1

Conditions

Breast Neoplasms 305Carcinoma, Non-Small-Cell Lung 287Colorectal Neoplasms 159Prostatic Neoplasms 158Carcinoma, Hepatocellular 144Neoplasms 137Leukemia, Myeloid, Acute 131Lung Neoplasms 117Squamous Cell Carcinoma of Head and Neck 108Multiple Myeloma 104Triple Negative Breast Neoplasms 102Recurrence 101Pancreatic Neoplasms 96Stomach Neoplasms 94Ovarian Neoplasms 89Neoplasm Metastasis 87Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Esophageal Neoplasms 68Uterine Cervical Neoplasms 67Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Melanoma 67Brain Neoplasms 67Rectal Neoplasms 64Head and Neck Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 58Myelodysplastic Syndromes 55Lymphoma 55Esophageal Squamous Cell Carcinoma 54

Interventions

enasidenib 1abemaciclib 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Chondrosarcoma × Clear all
NCT06176989 2026-04-28

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

NCT04040205 2025-07-20

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Medical College of Wisconsin

Phase 2 Recruiting
44 enrolled
Other solid neoplasmSarcoma

Chondrosarcoma, Retinoblastoma, Sarcoma, Osteosarcoma

NCT04673942 2024-10-26

BETA-PRIME

EpicentRx, Inc.

Phase 2 Recruiting
140 enrolled
Sarcoma

Adenoviridae Infections, Chondrosarcoma, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡